Uit de Q2 call GLPG:
Sofie Van Gijsel -- Senior Director Investor Relations
Thank you, and welcome all to the audio webcast of Galapagos' H1 2021 results. I am Sofie Van Gijsel, Investor Relations, representing the reporting team at Galapagos. This recorded webcast is accessible via the Galapagos website homepage and will be available for downloads and replay later on today.
We would like to remind everyone that we will be making forward-looking statements during today's webcast. These forward-looking statements include remarks concerning future developments of the pipeline and our Company and possible changes in the industry and competitive environment. Because these forward-looking statements involve risks and uncertainties, Galapagos' actual results may differ materially from the results expressed or implied in these statements.
Today's speakers will be Onno van de Stolpe, CEO, Dr. Walid Abi-Saab, CMO; and Bart Filius, COO and President. Onno will reflect on the operational highlights and Walid will speak to the topline results of our TYK2 and SIK2/3 programs released in July. Then, Bart will go over the financial results and end with expected news flow for the year.
Benzinga vandaag over stoppen Onno:
After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership.
He will stay in his role until a successor is found.
The company has kicked off a search for a new CEO. Van de Stolpe was a co-founder of Galapagos and has been CEO since it was formed in 1999.
His departure comes after a tricky period for Galapagos, which van de Stolpe alludes to in his retirement announcement, saying: "Despite recent setbacks, we continue to progress a deep pipeline of novel target-based compounds, while the commercial roll-out of our first approved product is underway,"
Galapagos is in the midst of launching its JAK1 inhibitor Jyseleca (filgotinib) for rheumatoid arthritis in Europe and Japan. However, the FDA rejected the drug as part of a wider investigation into the safety of the class.
The delay resulted in Galapagos' longstanding partner Gilead Sciences Inc (NASDAQ: GILD) abandon plans to develop the drug for rheumatoid arthritis in the US and handing back European marketing rights to Galapagos.
Last month, Galapagos' SIK inhibitor GLPG3970 failed two of three clinical trials.
Related Content: Galapagos SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients.
Also Read: Galapagos, Gilead Sciences Pull Plug On Ziritaxestat Clinical Trials.
Price Action: GLPG shares are up 8.64% at $59.72 during the premarket session on the last check Tuesday.